TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TAVR or SAVR? Cardiologists and heart surgeons highlight the care that goes into each decision
When heart patients require aortic valve replacement, would they be a better fit for TAVR or SAVR? Such decisions are not made lightly, clinicians emphasized in a new joint statement.
Advanced AI helps 3D imaging labs evolve with the times
“Technology grows and grows,” as one lab director explained. “Our job is to keep up with it and use it in the most efficient and effective way.”
New ways to predict TAVR outcomes for individual heart patients
As TAVR continues to gain popularity, researchers remain focused on discovering new ways to predict short- and long-term outcomes. One recent study, for example, explored the potential of AI-enabled imaging assessments. Another analysis focused on the CALLY index.
Stroke prevention devices for TAVR fail to make an impact
Cerebral embolic protection devices are "compelling," researchers wrote, but current data does not suggest they make a significant impact on patient outcomes.
Redo TAVR: Supra-annular, intra-annular valves linked to comparable outcomes
When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival.

TAVR or SAVR? Cardiologists and heart surgeons highlight the care that goes into each decision

When heart patients require aortic valve replacement, would they be a better fit for TAVR or SAVR? Such decisions are not made lightly, clinicians emphasized in a new joint statement.

Kimberly Hatch, RT(R)(CT)(ARRT), technical director of 3D lab at Banner Health, explains the advances in advanced visualization software what is needed to build a comprehensive cardiac 3D imaging lab.

Advanced AI helps 3D imaging labs evolve with the times

“Technology grows and grows,” as one lab director explained. “Our job is to keep up with it and use it in the most efficient and effective way.”

New ways to predict TAVR outcomes for individual heart patients

As TAVR continues to gain popularity, researchers remain focused on discovering new ways to predict short- and long-term outcomes. One recent study, for example, explored the potential of AI-enabled imaging assessments. Another analysis focused on the CALLY index.

Stroke prevention devices for TAVR fail to make an impact

Cerebral embolic protection devices are "compelling," researchers wrote, but current data does not suggest they make a significant impact on patient outcomes.

cardiologists evaluating the human heart to provide a treatment strategy

Redo TAVR: Supra-annular, intra-annular valves linked to comparable outcomes

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival.

Women live longer after TAVR than men

Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.

heart data research doctor cardiologist AI

Two separate studies explored the value of treating heart patients with tirzepatide.

Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban

When it came to all-cause mortality and ischemic stroke, however, the two popular DOACs were associated with comparable outcomes.